Pembrolizumab in the Treatment of Metastatic Non-Small Cell Lung Cancer

Authors
Kallem Sharat Venkat Reddy¹, Aakunuri Akhil², Dandyala Pavan Kalyan³
Pharm-D, Bharat Institute of Technology
Address: H-no.1-76, Shantinagar, Vanasthalipuram
Hyderabad, Telangana-500070, India

Abstract
In the last ten years, immune control point inhibitors (ICPI's) have been one of the most significant breakthroughs in cancer therapy. Different studies have reported desired clinical activity and durable response amongst advanced non-small cell lung cancer (NSCLC) patients in programmed cell death protein 1 (Pd-1) and programmed death ligand 1 (PD-L1). Such findings have led to changes in the current advanced NSCLC therapy methods, and a new standard first-line treatment option has been introduced for patients with PD-L1 positives. In October 2016, the United States Food and Drug Administration (US FDA) approved Pembrolizumab, a highly selective, humanised anti-PD-1 monoclonal antibody. Platinum-based chemotherapy is the first line treatment for advanced non-small cell lung cancer (NSCLC). Pembrolizumab replaced cytotoxic chemotherapy as the first line of treatment of choice in all patients with a tumour ratio score of 50% or higher for programmed death ligand 1 (PD-L1). Pembrolizumab was significantly higher in chemotherapy than chemotherapy with desirable responses and progressions free survival.

Keywords: Pembrolizumab, NSCLC, PD-L1, ICPI, Keytruda, Tumour Proportion Score.

Introduction
The main cause of cancer mortality in the world is lung cancer. American studies of epidemiology and end-results show that only 18.6 percent of patients survive 5 years or longer after diagnosis with lung cancer; overall 5 year lifetime survival (OS) was just 4.7 percent with patients with remote metastasis. Any lung cancer patients do not have this optimistic view. Increased advancements in targeted therapy and immunotherapy, especially in non small-cell lung cancer (NSCLC). While selective care for NSCLC patients with the respective driving mutations for several years remains a resourceful procedure, immunotherapy, designed to resolve immune evasion, is a recent clinical strategy and has shown positive effects in a proportion of NSCLC patients. Immune evasion is among the characteristics of cancer that prohibits immune systems from detecting tumour cells. Hence, the mechanism does not provide a successful antitrust response. Immune regulation ligands and the release of immune inhibitory molecules play a significant role in NSCLC immune evasion. The most commonly observed immune control point ligand in the NSCLC, the programmed cell death-1 ligand (PD-L1) has shown an immense
upregulation of PD-L1 expression. PD-1 is a costimulatory receptor that represses the surface of the lymphocytes of T-activation. PD-1’s bonding to PD-L1 stops the cytotoxic TL reaction and causes the immune system to escape. Both anti-PD-1 and anti-PD-L1 anti-compounds are blocking the PD-1 / PD-L1 pathway with positive NSCLC antifungal results and recommended anti-contractors.\(^{(1)}\)

Pembrolizumab is a humanised, highly purified, specifically PD-1 monoclonal antibody of IgG4 that inhibits the receptor of PD-1 / PD-L1. Pembrolizumabe has shown impressive and positive NSCLC efficacy and appropriate toxicity in all previous series of clinical studies, either as monotherapy or in combination with chemotherapy.

The Immune Checkpoint Inhibitors (ICPI’S):
Immune control points are the primary immune system regulators that can mitigate an immune response to an immunological stimulation when activated. A multitude of cancers can be avoided from being targeted by the host system by activating thresholds for immune response. It will bypass immune control points and improve the role of the immune system. Inhibitors of the immune checkpoint function by removing a natural trigger on the immediate response, so the immune cells or tubs can recognise and fight the tumours. The inhibitors are known as Immune Checkpoint Inhibitors. This treatment is often called an immune control point blockade since the immune cell molecule – the control point – is inhibited by the medication as a braking mechanism \(^{(2)}\)

Programmed Cell Death Protein 1(PD-1):
The PD-1 and CD-279 (differentiation cluster 279) programmed death protein 1 is a protein located on the surface of cells, which plays a key role in sustaining the immune system's response to human body cells by down regulating and improving auto-tolerance by suppressing inflammatory activity of T cells. The immune system should stop tumour cells being destroyed, but autoimmune conditions can also be prevented. PD-1 is an immune control point that has two pathways to shield against autoimmunity. Next, it facilitates antigen-specific T-cell apoptosis (programmed cell death) in lymph nodes. Second, it diminishes apoptosis (anti-inflammatory suppressive T cells) in regulatory T cells. \(^{(3)(4)(5)}\)

The Programmed Death-Ligand 1 (PD-L1):
The process and implement-ligand one (PD-L1) is a protein that is found in humans and is additionally referred to as B7-homolog one (B7-H1).nplay an significant function during certain cases, such as gestations, tissue allografts, autoimmune diseases and other illnesses, such as
liver disease, to block the conciliatory arm of an immune system.

PD-L1 is bound to the PD-1 receptor, used in activated cell T, B, and myeloid cells, to control activation or inhibition.

Studies have shown that the up regulation(1) of the PD-L1 can allow the tumours to escape from the host system.

An early analysis of 196 tumour tumours in nephritic cell cancer revealed a high tumour aggressiveness and a 4.5-fold elevated risk of death with the main expression of PD-L1 .(6)(7)

**Figure 3** The Micrographs Showing A PD-L1 Positive Lung Carcinoma, PD-L1 Immunostatin(6)(7)

**The Tumor Proportion Score (TPS):**
The expression of the PD-L1, which is the percentage of potential tumour cells with a partial or absolute membrane stain, is measured by means of Tumor Proportion Score (TPS). The specimen is called PD-L1, if the tuberous membrane is marked at some strength at 50 percent of feasible tumour cells.(8)

**Pembrolizumab**
The humanised antibody used in cancer immunotherapy is Pembrolizumab (formerly known as lambrolizumab, Keytruda brand). This is used to curate the lung cancer, Hodgkin lymphoma, cancer of the head and neck and melanoma of the chest. Poor injection supplies it intravenously.

Itchiness, swelling, cough, headache, nausea, and constipation are typical adverse effects of pembrolizumab.

It is an IgG4 isotype antibody that obstructs and helps the immune system to fight against and destroy the defence function of cancer cells. The major target site of pembrolizumab is the programmed death cell protein 1 (PD-1) lymphocyte receptor.

In the United States it was licenced in 2014 for medicinal use. For any unresectable or metastatic solid cancer with such genetic defects (mismatched repair failure or microsatellite instability), the United States Food and Drug Administration (USFDA) approved the disease in 2017. (9)(10)

![Formula of Keytruda (Pembrolizumab)](image)

**Pembrolizumab**

| Molar mass | -146-149kDag.mol⁻¹ |
|------------|-------------------|
| Class      | Antineoplastic agent |
| Route of administration | Intravenous |
| Type       | Monoclonal whole antibody |
| Not for    | Pregnant women |
| Manufacture | It is recombinantly manufactured in Chinese hamster(mouse) ovary (CHO) cells. |

**Brand Name for Pembrolizumab:**
KEYTRUDA is the name of Pembrolizumab’s brand.
Dose levels of Pembrolizumab:
In patients with metastatic or unresectable melanoma, the recommended dose of KEYTRUDA (pembrolizumab) is 200 mg intravenously given for 30 minutes every 3 weeks until the disease progresses or becomes unacceptable.\(^{(12)}\)

Fig 5 Brand of Pembrolizumab

Mechanism Action of Pembrolizumab
In general, pembrolizumab is a therapeutic antibody, which binds and inhibits PD-1 from being contained in lymphocytes. Normally the immune system prevents its own tissue from attacking; it is a so-called point of immune regulation. Many cancers generate proteins that are bound to PD-1 to keep the body from targeting and removing cancer alone. The PD-1 inhibition stimulates lymphocytes and allows the immune system to find and destroy carcinogenic cells; the immune system also protects their own bodies; and in some cases the immune system develops side-effects from immune dysfunction, for example Pembrolizumab.

Tumors with mutations are also known to contain a great many mutant proteins, which may serve as a marker of tumour; pembrolizumab is likely to promote the clearance of some such tumour by the immune system, keeping the system from stopping the clearance. The tumour triggers a further loss of microsatellite stability.\(^{(13)}(14)(15)(16}\)

Fig 6 Pembrolizumab activates the immune cell's PD-1 control point protein to reduce the immune response.\(^{(17)}\)

Pharmacology of Pembrolizumab
Pembrolizumab is eliminated from the bloodstream by non-specific catabolism, no metabolist drug reactions and no removal routes experiments have been carried out. The systemic clearance rate is approximately 0.2 L / day and is around 25 days.\(^{(12)}\)

Contraindications for Pembrolizumab
If a person is been with corticosteroids or immunosuppressive agents, such medications may stop before pembrolizumab begins as they can interfere with pembrolizumab therapy.

Pembrolizumab cannot be contraception for pregnant women and should not be given because animal experiments showed that foetal resistance can be compromised and that the risk of error could increase. It is unclear whether pembrolizumab is found in breast milk.\(^{(12)}\)

Common Adverse Reactions
The adverse effects include fatigue, pruritus and diminished appetite, rash, dyspnea, constipation and nausea.\(^{(5)}(18}\)

Factors in Choosing Initial Therapy for NSCLC
In patients with PD-L1 expression, monotherapy with the anti-PD-1 pembrolizumab antibody is
usually performed up to 50%. However, certain patients with rapidly evolving or extremely severe disorder may be treated with platinum doublet chemotherapy and pembrolizumab for effe with effe. The amount with PD-L1 expression, disease course and histology affect care in NSC LC. The combination of platinum double chemical therapy with pembrolizumab is normal and successful for patients with PD-L1 expression < 50 percent. Chemotherapy is determined by histology for those obtaining it.\(^{(19)}\)

Fig 7 Factors In Choosing Initial Therapy For Nsclc:

1. **EGFR**: The Epidermal growth factor receptor
   *Epidermal growth factor receptor* is a tyrosine kinase transmembrane receptor found in some normal neurogenic, monenchymal tissue. EGFR over expression and pathogenesis include a variety of human malignants such as NSCLC has been reported.

2. **ALK**: The Anaplastic lymphoma kinase
   Lung cancer with a "*Anaplastic lymphoma kinase* rearrangement" occurs when a portion of the ALK chromosome occurs disrupted (or mutated) due to unregulated cell replication.

3. **ROS-1**: c-ros oncogene 1Rearrangements of ROS1 genes were initially described in glioblastoma and are now recognised in a variety of malignancies, including NSCLC.

4. **BRAF V600E**: V600E is a BRAF gene mutation in which valine (V) at amino acid 600 is replaced by glutamic acid (E)
   Up to 3.5–4 per cent of patients with non-small cell lung cancer (NSCLC) report BRAF gene mutations.

**Treatment:**

In patients with:
- **PD-L1-Low (<50 Percent Expression):**
  The combination of Pembrolizumab with chemotherapy:
  Pembrolizumab approved by the US Food and Drug Administration (FDA) for the first-line treatment of metastatic NSCLC in conjunction with carboplatin and pemetrexed, independent of low or high expression programmed cell death
ligand 1 (PD-L1) For those with < 50 per cent PD-L1 expression or unexplained advanced adenocarcinomas, this is recommended method of combined therapy. Pembrolizumab in clinical trials has been shown to have good efficacy and a non-intersecting chemotherapy toxicity profile, and the use of traditional pembrolizumab chemotherapy in the first line therapy has been shown to be very appropriate. By way of cytotoxic results and immune system modulation, chemotherapy eradicates cancer cells. By way of cytotoxic results and immune system modulation, chemotherapy eradicates cancer cells. Chemotherapy has shown that this increases tumour antigen crosspresentation, reduces the activity of the T-regulatory cell and induces PD-L1 expression on cancer cells that may have symbiotic antitumor effects with pembrolizumab treatment.

**Non Squamous**
Therapy dependent on pembrolizumab – Pembrolizumab (200 mg intravenously every three week) in mature, non-squamous NSCLC has stronger and more advantageous results relative to chemical therapy alone, in platinum-doublet chemotherapy (platinum agent and pemetrexed).

**Squamous**
In addition to platinius double-chemotherapy, frontline pembrolizumab also has increased squamous cell tumour outcomes without inducing significant toxicity.

**Less-Favored Options:**
While pembrolizumab and chemotherapy are prescribed in most PD-L1-low tumours (1-49%), monotherapy pembrolizumab is seen as an alternative for low-PD-L1 (but not in PD-L1-negative tumours). Pembrolizumab is an experimental medication.

- **PD-L1-High (>50 Percent Expression)**
  This expression levels of PD-L1 can be seen in around 30 per cent of advanced NSCLC patients. (22)

  - **In Absence of Rapidly Progressive Disease:**
    **Pembrolizumab monotherapy**
    Pembrolizumab is approved for frontline therapy by the FDA for patients with advanced EGFR / ALK wild-type NSCLC whose tumours have an expression of around 50 percent PD-L1. Generally, pembrolizumab monotherapy is prescribed for such patients.
    The NSCLC treatment dose for patients with non-progression disease is “ 200 mg prescribed as a pembrolizumab-labelled infusion for 30 min every 3 weeks before disease progression, unacceptable toxicity or for up to 24 months ” Also applicable for all approved NSCLC indications. In the two registration trials, KN010[27] and KN024, this branded product implements the total 35-dose (2-year) period of pembrolizumab treatment specified in protocol. [28]
    Patients with development of the disease is liable for additional second course of pembrolizumab (up to 17 doses/1 year) after completing 35 doses. In the absence of increasingly progressing disorder pembrolizumab monotherapy is favoured.

  - **In Presence of Rapidly Progressive Disease:**
    **Pembrolizumab plus chemotherapy:**
    Existential treatment with pembrolizumab and chemotherapy are recommended for patients with increasingly progressing cancer or a tumour combination that leads to early relapse to deterioration that avoids chemotherapy in the second phase. This strategy is close to PD-L1-low tumours.

- **Pembrolizumab for nonsmall cell lung cancer with brain metastases:**
  About 25 – 40% of all NSCLC patients ultimately develop brain metastases during their disorder. In this case, radiotherapy (stereotactic
radiation or brain-wide radiation), addressing treatments and procedures of patients chosen are used in the clinical strategy.

Pembrolizumab remains uncertain regarding the function of NSCLC brain metastases, and more clinical study is required..\(^{20\text{)(21)(22)(23)}\)

**Biomarkers For Pembrolizumab**

Pembrolizumab has been demonstrated to give better clinical performance, consistent and effective responses and appropriate toxicity, which make it a valuable indicator for care of advanced NSCLC patients. Unfortunately, pembrolizumab does not help everyone; less than 1 percent of patients with advanced NSCLC have reported favourable reactions with monotherapy with pembrolizumab. It is therefore crucial to establish accurate biomarkers to recognise more likely pembrolizumab patients. The rationale of immunotherapy blockade PD-L1 is to untie pre-existing tumor-related T-cells to achieve anti-tumping results.

The effectiveness of a PD-1 blockade depends on two aspects: an immunosuppressive micro-environment tumour (TME) under which the PD-1 / PD-L1 interactions can not work, and the immunogenicity of the tumour, which indicates the involvement of neo-antigenic products from the tumour. The predictive biomarkers for pembrolizumab can thus be classified primarily in two categories: the tumour immunogenic and the T-cell inflamed TME (TME).\(^{24}\)

**Safety of Pembrolizumab in the Treatment of Nonsmall Cell Lung Cancer**

As well as the most part, pembrolizumab-associated adverse effects (AEs) occurred and patients including exhaustion (10.4% – 19.4%), reduced appetite (10% – 14%), rashes (9% – 13%), diarrhoea (6% -14.3%) and nausea (7.5% – 11%) with low grades in general. Grade 3 or higher EIs is reported to be significantly smaller than those of chemical therapy in 9.5 percent-26.6 percent (35 percent -53.3 percent) of patients with pembrolizumab monotherapy. The AEs is largely manageable; but the pembrolizumab resistant AEs (IRAEs) are of great importance. Pembrolizumab reactivates antimicrobial reactivity and contributes to extremely rare autoimmune toxicity termed IrAEs as it inhibits PD-1 / PD-L1 interaction, as other immune regulates inhibitors do. Hypothyroidism (6.7%-9.1%), pneumonitis (3.6%-6.5%) and hyperthyroidism (4%-7.8%) were among the most popular irAEs. Colitis, extreme skin reactions, infusion reactions and IrAEs of grade 3 or above were less than 2 percent, with a rare (< 1 percent) and pneumonitis- pancreatitis are all part of other AEs related mortality. Deaths associated with pembrolizumab. As pembrolizumab has risen in a wide range of cancers, including NSCLC, the number of patients with potentially lethal pneumonitis grows beyond doubt; knowing the clinical and radiological characteristics of pneumonitis would also help to diagnose early, maximise treatment and enhance results..\(^{25\text{)(26)}\)

**Conclusion**

The use of Pembrolizumab in traditional Pemetrexed Chemotherapy and Platinum dependent medications resulted in significantly more overall survival and progression-free survival in patients with previously diagnosed non-treated metastatic NSCLCs without EGFR or ALK mutations than chemical therapy alone. The side-effect profile in Pembrolizumab was appropriate and anti-cancer activity demonstrated in advanced NSCLC patients.

In at least 50 percent or more of tumour cells, increased pembrolizumab efficacy was shown in patients with PD-L1 expression. For advanced EGFR / ALK wild type NSCLC patients with a 50% PD-L1 expression in their tumours, the pembrolizumab is active in the front line. Pembrolizumab monotherapy has demonstrated long term effects in these cases. Pembrolizumab is now labelled at 200 mg intravenously per third week for up to 24 months (35 doses) in the treatment of non-small-cell lung cancer (NSCLC). However, the optimal period of
advanced pembrolizumab and other immune response point inhibitors therapy of NSCLC has been the focus for ongoing clinical research.

References

1. Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer cell, 27(4), 450-461.

2. Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nature reviews Drug discovery, 14(8), 561-584.

3. Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12)

4. Francisco LM, Sage PT, Sharpe AH (July 2010). "The PD-1 pathway in tolerance and autoimmunity". Immunological Reviews. 236: 219–42.

5. Fife BT, Pauken KE (January 2011). "The role of the PD-1 pathway in autoimmunity and peripheral tolerance". Annals of the New York Academy of Sciences. 1217: 45–59.

6. Butte MJ, Peña-Cruz V, Kim MJ, Freeman GJ, Sharpe AH (August 2008). "Interaction of human PD-L1 and B7-1". Molecular Immunology. 45 (13): 3567–72.

7. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boullassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP (April 2010). "Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection". Nature Medicine. 16 (4): 452–9.

8. Michaelidou, K., Agelaki, S., & Mavridis, K. (2020). Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises. Expert Review of Molecular Diagnostics, 20(3), 335-344.

9. FDA approves pembrolizumab for advanced esophageal squamous cell cancer". U.S. Food and Drug Administration (FDA) (Press release). 30 July 2019. Retrieved 10 January 2020.

10. Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12)

11. Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Retrieved 10 January 2020.

12. Keytruda 50 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 25 November 2019. Retrieved 10 January 2020.

13. Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L (July 2010). "The PD-1 pathway in tolerance and autoimmunity". Immunological Reviews. 236: 219–42

14. Buqué, Aitziber (April 2015). "Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications". Oncoimmunology.

15. Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews Cancer. 12 (4): 252–64.

16. Bala S, Nair A, Lemery S, et al. (30 May 2017). "FDA D.I.S.C.O.: First Tissue/Site
Agnostic Approval Transcript”. U.S. Food and Drug Administration (FDA).

17. https://www.cancer.gov/news-events/cancer-currents-blog/2015/pembrolizumab-nscle

18. Linardou, Helena; Gogas, Helen (July 2016). "Toxicity management of immunotherapy for patients with metastatic melanoma". Annals of Translational Medicine. 4 (14): 272

19. Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. S., & Adjei, A. A. (2019, August). Current diagnosis and management of small-cell lung cancer. In Mayo Clinic Proceedings (Vol. 94, No. 8, pp. 1599-1622). Elsevier.

20. Pai-Scherf, L., Blumenthal, G. M., Li, H., Subramaniam, S., Mishra-Kalyani, P. S., He, K., … & McKee, A. E. (2017). FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. The oncologist, 22(11), 1392.

21. Lim, S. H., Sun, J. M., Lee, S. H., Ahn, J. S., Park, K., & Ahn, M. J. (2016). Pembrolizumab for the treatment of non-small cell lung cancer. Expert opinion on biological therapy, 16(3), 397-406.

22. Dang, T. O., Ogunniyi, A., Barbee, M. S., & Drilon, A. (2016). Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert review of anticancer therapy, 16(1), 13-20.

23. Malhotra, J., Jabbour, S. K., & Aisner, J. (2017). Current state of immunotherapy for non-small cell lung cancer. Translational lung cancer research, 6(2), 196.

24. Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015). Immune checkpoint blockade in cancer therapy. Journal of clinical oncology, 33 (17), 1974.

25. Qin, Q., & Li, B. (2019). Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions. Journal of cancer research and therapeutics. 15(4), 743.

26. Rihawi, K., Gelsomino, F., Sperandi, F., Melotti, B., Fiorentino, M., Casolari, L., & Ardizzoni, A. (2017). Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. Therapeutic advances in respiratory disease, 11(9), 353-373.

27. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540–1550 (2016). Crossref, Medline, CAS, Google Scholar

28. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016). Crossref, Medline, CAS, Google Scholar

29. Fvasconcellos (talk • contribs) – From PDB entry 5DK3. More information: Scapin G, Yang X, Prosise WW, et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol 2015; 22(12):953-8.